Assessment of thromboembolic risk in patients with gynecological cancer in a hospital in Salvador, Bahia, Brazil
DOI:
https://doi.org/10.21527/2176-7114.2026.51.17200Keywords:
Anticoagulants, Female Genital Neoplasms, Venous Thromboembolism, HematologyAbstract
Introduction: Among acute cardiovascular diseases, venous thromboembolism is one of the most common complications in patients with gynecological cancer, due to prothrombotic state and exposure to vasculotoxic therapies. Objective: To evaluate the thromboembolic risk and the profile of anticoagulant use for prevention or treatment of VTE in patients with gynecological cancer, followed up in a specialized hospital. Methods: A cross-sectional study was carried out at the Hospital da Mulher, located in Salvador, Bahia in 1 year, consisting of analysis of medical records to track the profile of use and application of the Khorana, PROTECHT and Onkotev scores. Results: The electronic medical records of a population of 2,865 women were evaluated, and 117 patients were selected, with a mean age of 57.20 years. Malignant neoplasm of the cervix (42.74%) was the most frequent. The ROC curve determined that Onkotev score presented a better performance predictive of thromboembolic risk (AUC = 0.742; p = 0.000; CI-95: 0.651-0.833) in this sample than the Khorana (AUC = 0.567; p = 0.208; CI-95: 0.463-0.671) and PROTECHT (AUC = 0.517, p = 0.730, CI-95: 0.413-0.624) scores. Conclusion: This study is one of the first in Bahia to investigate the profile of anticoagulant use in this group. Onkotev presented itself as the one with the best performance among the others, however, its predictive accuracy remains limited, since it would be able to predict approximately 75% of the VTE cases that occurred. Further studies are needed to evaluate this topic.
References
1. Mansur AP, Favarato D. Taxas de Mortalidade por Doenças Cardiovasculares e Câncer na População Brasileira com Idade entre 35 e 74 Anos, 1996-2017. Arq Bras Cardiol. 2021;117(2):329-40. Available from: https://doi.org/10.36660/abc.20200233.
2. Ibrahim E, Norris LA, Saadeh FA. Update on extended prophylaxis for venous thromboembolism following surgery for gynaecological cancers. Thrombosis Update. 2021;2:100038. Available from: https://www.sciencedirect.com/science/article/pii/S2666572721000079.
3. Faria Júnior TF. Câncer de Ovário. Boletim TelessaúdeBa. 2022;9(10). Available from: http://telessaude.saude.ba.gov.br/wp-content/uploads/2022/10/20221010_Boletim-2022_outubro2.pdf.
4. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197-e206. Available from: https://doi.org/10.1016/S2214-109X(22)00501-0.
5. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2023: incidência do Câncer no Brasil. Rio de Janeiro: INCA; 2022. Available from: https://www.gov.br/inca/pt-br/assuntos/cancer/numeros/estimativa.
6. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária (ANVISA). Resolução da Diretoria Colegiada – RDC n° 406, de 22 de julho de 2020, dispõe sobre Boas Práticas de Farmacovigilância para Detentores de Registro de Medicamento de uso humano, e dá outras providências. Diário Oficial da União, Poder Executivo, Brasília, DF; 2020. Available from: https://www.in.gov.br/en/web/dou/-/resolucao-de-diretoria-colegiada-rdc-n-406-de-22-de-julho-de-2020-269155491.
7. Costa AG da, Costa MSC R, Ferreira E da S, Sousa PC de, Santos MM dos, Lima DE de O B, et al. Conhecimento dos Profissionais de Enfermagem sobre Segurança do Paciente Oncológico em Quimioterapia. Rev Bras Cancerol. 2019;65(1):e04274. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/274.
8. Van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mahé I, Wilts IT, Twint DC, Porreca E, Arrieta O, Stépanian A, Smit K, De Tursi M, Bleker SM, Bossuyt PM, Nieuwland R, Kamphuisen PW, Büller HR. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102(9):1494-1501. Available from: https://doi.org/10.3324/haematol.2017.169060.
9. Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, Tufano A, Lordick F, De Simone B, Muehlberg KS, Bruzzese D, Attademo L, Arturo C, Sodano M, Moretto R, La Fata E, De Placido S. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. Oncologist. 2017;22(5):601-608. Available from: https://doi.org/10.1634/theoncologist.2016-0246
10. Xiong W. Current status of treatment of cancer-associated venous thromboembolism. Thrombosis J. 2021;19(21). Available from: https://doi.org/10.1186/s12959-021-00274-x.
11. INCA. Instituto Nacional de Câncer. Mortalidade conforme a localização primária do tumor e sexo. Estatísticas de Câncer. 2020. Disponível em: https://www.gov.br/inca/pt-br/assuntos/cancer/numeros. Acesso em: 18 abr 2023.
12. Santos MO, Lima FC da S de, Martins LFL, Oliveira JFP, Almeida LM de, Cancela M de C. Estimativa de incidência de câncer no Brasil, 2023-2025. Rev Bras Cancerol. 2023;69(1):e213700. DOI: 10.32635/2176-9745.RBC.2023v69n1.3700. Disponível em: https://rbc.inca.gov.br/index.php/revista/article/view/3700. Acesso em: 14 jan 2025.
13. OLAWAIYE, A. B.; CUELLO, M. A.; ROGERS, L. J. Cancer of the vulva: 2021 update. International Journal of Gynecology & Obstetrics, v. 155, Suppl. 1, p. 7-18, 2021. DOI: 10.1002/ijgo.13881. Disponível em: https://doi.org/10.1002/ijgo.13881. Acesso em: 18 jan. 2025.
14. Sam A, George J, Mathew B. Less common gynecologic malignancies: an integrative review. Semin Oncol Nurs. 2019;35(2):175-81. DOI: 10.1016/j.soncn.2019.02.004. Epub 2019 Mar 11. Disponível em: https://doi.org/10.1016/j.soncn.2019.02.004. Acesso em: 10 jan 2025.
15. Santos MAP dos, Fernandes FCG de M, Santos EG de O, Bezerra de Souza DL, Barbosa IR. Tendências de incidência e mortalidade por câncer de ovário nos países da América Latina. Rev Bras Cancerol. 2020;66(4):e06813. Disponível em: https://rbc.inca.gov.br/index.php/revista/article/view/813. Acesso em: 16 nov 2023.
16. Paulino E, Melo AC de, Silva-Filho AL, Maciel LF, Thuler LCS, Goss P, et al. Panorama of gynecologic cancer in Brazil. JCO Global Oncol. 2020;6:1617-30. DOI: 10.1200/GO.20.00099. Disponível em: https://doi.org/10.1200/GO.20.00099. Acesso em: 10 jan 2025.
17. Burihan MC, [et al.]. Consenso e atualização na profilaxia e no tratamento do tromboembolismo venoso. 1. ed. Rio de Janeiro: Guanabara Koogan; 2019.
18. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2023;41(16):3063-3071. doi: 10.1200/JCO.23.00294. Available from: https://ascopubs.org/doi/10.1200/JCO.23.00294.F
19. Polo TC, Miot HA. Aplicações da curva ROC em estudos clínicos e experimentais. J Vasc Bras. 2020;19:e20200186. doi:10.1590/1677-5449.200186. Available from: https://doi.org/10.1590/1677-5449.200186
20. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2023;41(16):3063-3071. doi: 10.1200/JCO.23.00294. Available from: https://ascopubs.org/doi/10.1200/JCO.23.00294.F
21. Ramos-Esquivel A, Hernández-Romero G, Marenco-Flores A, Umaña C, Céspedes-Calvo A, Mora-Hidalgo R. Comparison among three predictive models for cancer-associated thromboembolism in a Hispanic population. J Clin Oncol. 2023;41(Suppl 16):e24074-e24074. doi:10.1200/JCO.2023.41.16_suppl.e24074. Available from: https://doi.org/10.1200/JCO.2023.41.16_suppl.e24074
22. Arafah Y, Al-Juhaishi T, Abu Zeinah G, Nayak LV, Al-Kindi S. Performance of Khorana score to predict one-year risk of venous thromboembolism in over two million patients with cancer. Blood. 2020;136(Suppl 1):52–3. doi:10.1182/blood-2020-139706. Available from: https://doi.org/10.1182/blood-2020-139706
23. Guman NAM, van Geffen RJ, Mulder FI, van Haaps TF, Hovsepjan V, Labots M, et al. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer. J Thromb Haemost. 2021 Dec;19(12):2974–83. doi:10.1111/jth.15503. Available from: https://www.jthjournal.org/article/S1538-7836(22)00538-4/fulltext
24. Xiong W, Zhao Y, Du H, Wang YW, Xu M, Guo X. Optimal authoritative risk assessment score of cancer-associated venous thromboembolism for hospitalized medical patients with lung cancer. Thromb J. 2021;19:95. doi:10.1186/s12959-021-00339-x. Available from: https://doi.org/10.1186/s12959-021-00339-x
25. Cella CA, Fazio N, Lordick F, Bagnardi V, Frassoni S, Gervaso L, et al. Comparison of Khorana vs. Onkotev predictive score to individualize anticoagulant prophylaxis in ambulatory patients with cancer. Blood. 2023;142(Suppl 1):661. doi:10.1182/blood-2023-172815. Available from: https://doi.org/10.1182/blood-2023-172815
26. Di Nisio M, van Es N, Rotunno L, Anzoletti N, Falcone L, De Tursi M, et al. Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. J Thromb Thrombolysis. 2019 Jul;48(1):125–33. doi:10.1007/s11239-019-01845-6. Available from: https://doi.org/10.1007/s11239-019-01845-6
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Marlane Marna Santos e Santos, Rosa Malena Fagundes Xavier, Maria Teresita Del Niño Jesus Fernandez Bendicho
This work is licensed under a Creative Commons Attribution 4.0 International License.
By publishing in Revista Contexto & Saúde, authors agree to the following terms:
The works are licensed under the Creative Commons Atribuição 4.0 Internacional (CC BY 4.0) license, which allows:
Share — to copy and redistribute the material in any medium or format;
Adapt — to remix, transform, and build upon the material for any purpose, including commercial.
These permissions are irrevocable, provided that the following terms are respected:
Attribution — authors must be properly credited, with a link to the license and indication of any changes made.
No additional restrictions — no legal or technological measures may be applied that restrict the use permitted by the license.
Notes:
The license does not apply to elements in the public domain or covered by legal exceptions.
The license does not grant all rights necessary for specific uses (e.g., image rights, privacy, or moral rights).
The journal is not responsible for opinions expressed in the articles, which are the sole responsibility of the authors. The Editor, with the support of the Editorial Board, reserves the right to suggest or request modifications when necessary.
Only original scientific articles presenting research results of interest that have not been published or simultaneously submitted to another journal with the same objective will be accepted.
Mentions of trademarks or specific products are intended solely for identification purposes, without any promotional association by the authors or the journal.
License Agreement (for articles published from September 2025): Authors retain copyright over their article and grant Revista Contexto & Saúde the right of first publication.
